HUP9700274A3 - Optically active (-)-(3r)-3-methyl-4-{4-[4-(4-pyridyl)-piperazin-1-yl]-phenoxy}-butiric acid as inhibitor of celle-adhesion, preparation and use of this compound, pharmaceutical composition containing this compound - Google Patents

Optically active (-)-(3r)-3-methyl-4-{4-[4-(4-pyridyl)-piperazin-1-yl]-phenoxy}-butiric acid as inhibitor of celle-adhesion, preparation and use of this compound, pharmaceutical composition containing this compound

Info

Publication number
HUP9700274A3
HUP9700274A3 HU9700274A HUP9700274A HUP9700274A3 HU P9700274 A3 HUP9700274 A3 HU P9700274A3 HU 9700274 A HU9700274 A HU 9700274A HU P9700274 A HUP9700274 A HU P9700274A HU P9700274 A3 HUP9700274 A3 HU P9700274A3
Authority
HU
Hungary
Prior art keywords
compound
celle
piperazin
phenoxy
pyridyl
Prior art date
Application number
HU9700274A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/457,538 external-priority patent/US5652242A/en
Priority claimed from GBGB9518188.9A external-priority patent/GB9518188D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of HU9700274D0 publication Critical patent/HU9700274D0/hu
Publication of HUP9700274A2 publication Critical patent/HUP9700274A2/hu
Publication of HUP9700274A3 publication Critical patent/HUP9700274A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HU9700274A 1995-06-01 1996-05-28 Optically active (-)-(3r)-3-methyl-4-{4-[4-(4-pyridyl)-piperazin-1-yl]-phenoxy}-butiric acid as inhibitor of celle-adhesion, preparation and use of this compound, pharmaceutical composition containing this compound HUP9700274A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/457,538 US5652242A (en) 1993-03-29 1995-06-01 Heterocyclic derivatives
GBGB9518188.9A GB9518188D0 (en) 1995-09-07 1995-09-07 Optically active derivative

Publications (3)

Publication Number Publication Date
HU9700274D0 HU9700274D0 (en) 1997-04-28
HUP9700274A2 HUP9700274A2 (hu) 1999-06-28
HUP9700274A3 true HUP9700274A3 (en) 2000-02-28

Family

ID=26307696

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9700274A HUP9700274A3 (en) 1995-06-01 1996-05-28 Optically active (-)-(3r)-3-methyl-4-{4-[4-(4-pyridyl)-piperazin-1-yl]-phenoxy}-butiric acid as inhibitor of celle-adhesion, preparation and use of this compound, pharmaceutical composition containing this compound

Country Status (31)

Country Link
EP (1) EP0796247A1 (fr)
JP (1) JP2885941B2 (fr)
KR (1) KR100245957B1 (fr)
AT (1) AT406675B (fr)
AU (1) AU710105B2 (fr)
BE (1) BE1009520A5 (fr)
BR (1) BR9606409A (fr)
CA (1) CA2194397A1 (fr)
CH (1) CH691808A5 (fr)
CZ (1) CZ26997A3 (fr)
DE (1) DE19680509T1 (fr)
DK (1) DK10697A (fr)
ES (1) ES2137886B1 (fr)
FI (1) FI970393A0 (fr)
GB (1) GB2304340B (fr)
GR (1) GR1002702B (fr)
HU (1) HUP9700274A3 (fr)
IE (1) IE960405A1 (fr)
IL (1) IL118477A0 (fr)
IT (1) IT1290839B1 (fr)
LU (1) LU90008B1 (fr)
MC (1) MC2418A1 (fr)
MX (1) MX9700379A (fr)
NL (1) NL1003243C2 (fr)
NO (1) NO307460B1 (fr)
NZ (1) NZ308597A (fr)
PL (1) PL318440A1 (fr)
SE (1) SE510812C2 (fr)
SK (1) SK13097A3 (fr)
TR (1) TR199700020T1 (fr)
WO (1) WO1996038416A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0100158A3 (fr) * 1982-07-28 1985-03-27 The Upjohn Company Hétéroalkysylalkanoles 3-pyridinyliques, leurs acides alkanoiques et leurs esters
GB8609630D0 (en) * 1986-04-19 1986-05-21 Pfizer Ltd Anti-arrhythmia agents
AU692438B2 (en) * 1993-03-29 1998-06-11 Astrazeneca Ab Heterocyclic derivatives as platelet aggregation inhibitors
EP0690847A1 (fr) * 1993-03-29 1996-01-10 Zeneca Limited Composes heterocycliques en tant qu'inhibiteurs de l'agregation plaquettaire

Also Published As

Publication number Publication date
NO970437D0 (no) 1997-01-31
HUP9700274A2 (hu) 1999-06-28
JP2885941B2 (ja) 1999-04-26
FI970393L (fi) 1997-01-30
SE9700203L (sv) 1997-01-24
IL118477A0 (en) 1996-09-12
ITMI961113A0 (it) 1996-05-31
NL1003243C2 (nl) 1996-12-04
NZ308597A (en) 1998-11-25
JPH09512836A (ja) 1997-12-22
AT406675B (de) 2000-07-25
EP0796247A1 (fr) 1997-09-24
CH691808A5 (de) 2001-10-31
TR199700020T1 (tr) 1997-04-22
MC2418A1 (fr) 1997-05-23
GB2304340A (en) 1997-03-19
GB9627127D0 (en) 1997-02-19
ES2137886B1 (es) 2000-08-16
ES2137886A1 (es) 1999-12-16
HU9700274D0 (en) 1997-04-28
CZ26997A3 (en) 1997-08-13
SE9700203D0 (sv) 1997-01-24
BR9606409A (pt) 1997-09-30
SE510812C2 (sv) 1999-06-28
BE1009520A5 (fr) 1997-04-01
NO307460B1 (no) 2000-04-10
GR1002702B (el) 1997-05-22
MX9700379A (es) 1997-04-30
FI970393A7 (fi) 1997-01-30
IT1290839B1 (it) 1998-12-14
ITMI961113A1 (it) 1997-12-01
AU5827296A (en) 1996-12-18
FI970393A0 (fi) 1997-01-30
LU90008B1 (fr) 1997-04-16
KR100245957B1 (ko) 2000-04-01
IE960405A1 (en) 1996-12-11
ATA900596A (de) 1999-12-15
DK10697A (da) 1997-04-01
GB2304340B (en) 1998-07-29
SK13097A3 (en) 1997-08-06
KR970704689A (ko) 1997-09-06
CA2194397A1 (fr) 1996-12-05
DE19680509T1 (de) 1997-12-04
NO970437L (no) 1997-02-20
PL318440A1 (en) 1997-06-09
AU710105B2 (en) 1999-09-16
WO1996038416A1 (fr) 1996-12-05

Similar Documents

Publication Publication Date Title
IL116325A (en) Substituted 4-(1,2,3,4-tetrahydro-1-naphthalenyl)-1h-imidazoles and substituted 4-(2,3-dihydro-1h-inden-1-yl)-1h-imidazoles the optically active isomers thereof and racemic mixtures thereof their preparation and pharmaceutical compositions containing them
TR199500825A2 (tr) Cok üniteli farmasötik müstahzar.
HUP0201275A3 (en) Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts and pharmaceutical composition containing the compound
AU1912197A (en) New inhibitors of metalloprotease, process for preparing them and pharmaceutical compositions containing them
FI973039A0 (fi) Uusia farnesyylitransferaasin inhibiittoreita, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
FI973279A0 (fi) Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset
GB8827391D0 (en) Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride
HUP0203376A3 (en) 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them and their use
IL143858A (en) 4-(aminomethyl)-piperidine benzamides, process for their preparation and pharmaceutical compositions containing them
ATE332894T1 (de) Ein pyridin-n-oxid-derivat und ein prozess zu seiner umsetzung in pharmazeutische wirkstoffe
AU3176695A (en) Transdermally active pharmaceutical composition containing 5-aminolaevulinic acid
GB8827390D0 (en) Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride
HUP0000960A3 (en) Spray-dried paroxetine hydrochloride, process for it's preparation,use of the compound and pharmaceutical compositions containing the same
UA41978C2 (uk) N-метил-n-[(1s)-1-феніл-2-((3s)-3-гідроксипіролідин-1-іл)етил]-2,2- дифенілацетамід гідрохлорид, спосіб його отримання та фармацевтична композиція
IL120984A (en) Salts of ethyl 3-(2-(4-(4-(amino-imino-methyl) phenyl)-4-methyl-2,5-dioxoimidazolidin-1-yl)acetylamino)-3-phenylpropionate, their preparation and pharmaceutical compositions containing them
CA2340734A1 (fr) Derive de pyridyl-4h-1,2,4-oxadiazine optiquement actif et son utilisation dans le traitement des maladies vasculaires
HUP9700274A3 (en) Optically active (-)-(3r)-3-methyl-4-{4-[4-(4-pyridyl)-piperazin-1-yl]-phenoxy}-butiric acid as inhibitor of celle-adhesion, preparation and use of this compound, pharmaceutical composition containing this compound
HUP0400889A3 (en) Processes for the preparation of (r)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and pharmaceutical compositions containing the compound
HUP9902316A3 (en) 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylic acid derivatives as endothelin antagonists and pharmaceutical compositions containing them
EE200100219A (et) (+)-alfa-(2,3-dimetoksüfenüül)-1-[2-(4-fluorofenüül)etüül]-4-piperidiinmetanooli estrid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
IL112604A (en) Derivatives of (2-(ar) alkyldithio indane-2-carboxamido) tricyclic-oxobenzazepine-carboxylic acid and similar compounds useful as inhibitors of enkephalinase and ace, their preparation and pharmaceutical compositions containing them
GB9610093D0 (en) (-)-(3R)-methyl-4-[4-[4-(4-pyridyl) piperazin-1-yl] phenoxy] butyric acid
IL114620A0 (en) 1-(4-(aminomethyl)phenyl)-substituted quinolonecarboxylic acids their preparation and pharmaceutical compositions containing them
ZA964509B (en) (-)-(3r)-3-methyl-4-{4-[4-(4-pyridyl)piperazin-1-yl]phenoxy}butyric acid
HUP0100056A3 (en) Carboxyl acid substituted heterocycles as metalloproteinase inhibitors, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing them